No Data
*Special Treat Jingfeng (000908.SZ): The holding subsidiary is planning to authorize and act as an agent for pharmaceutical products with related parties.
gelonhui on November 11th: *ST Jingfeng (000908.SZ) announced that its holding subsidiary Shanghai Jingfeng Pharmaceutical Co., Ltd. is planning to engage in daily related party transactions of authorized agent pharmaceutical products with its affiliate Hebei Zhongcheng Pharmaceutical Co., Ltd. (referred to as "Zhongcheng Pharmaceutical") for development needs. The amount of the related party transaction is expected to be no more than 30 million RMB, and the above limit is valid for one year from the date of approval by the shareholders' meeting. The main content of this daily related party transaction is for Shanghai Jingfeng to sell sodium glycoxylate injection to Zhongcheng Pharmaceutical and authorize Zhongcheng Pharmaceutical for exclusive sales promotion and distribution nationwide.
*ST Jingfeng: Report for the third quarter of 2024
*ST Jingfeng (000908.SZ): Intends to carry out commissioned research and development.
Gelonghui, October 18th | *ST Jingfeng (000908.SZ) announced that, according to the development needs, the company and its holding subsidiaries plan to engage in related-party entrusted research and development with the subsidiary of the related party CSPC Pharma Holdings Co., Ltd. (referred to as "CSPC Pharma Group"), named CSPC Pharma Group Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (referred to as "CSPC Zhongqi"), with a total expected transaction amount not exceeding 10 million yuan. The above limit is valid for three years from the date of approval by the board of directors.
ST Jingfeng (000908.SZ) subsidiary Shanghai Jingfeng plans to sell its property located in Suzhou city at a price of 64.6928 million yuan.
*ST Jingfeng (000908.SZ) announced that its wholly-owned subsidiary shanghai Jingfeng Pharmaceutical Co., Ltd. (referred to as "shanghai...
*ST Jingfeng (000908.SZ): Shareholder Ye Xiangwu completed a shareholding of 1.0448 million shares
On September 24, Gelunhui reported that Special Treat Jingfeng (000908.SZ) announced that the company recently received a notice from Mr. Ye Xiangwu regarding the completion of the shareholding plan of Hunan Jingfeng Pharmaceutical Co., Ltd. As of the disclosure date of the announcement, Mr. Ye Xiangwu has cumulatively increased the company's shareholding by 1.0448 million shares through the Shenzhen Stock Exchange trading system in a centralized bidding trading manner, accounting for 0.12% of the total share capital of the company. The total amount of the shareholding is 2,002,940 yuan (excluding transaction costs), and the shareholding amount has reached the lower limit of this shareholding plan. This shareholding plan has been completed.
*ST Jingfeng: 2024 Semi-Annual Report Summary
Even After Rising 19% This Past Week, Hunan Jingfeng PharmaceuticalLtd (SZSE:000908) Shareholders Are Still Down 49% Over the Past Five YearsNo Data
No Data
